Larimar Therapeutics Reports Q2 2025 Financial Results

Larimar Therapeutics ( (LRMR) ) has issued an announcement.

On August 14, 2025, Larimar Therapeutics reported its second quarter 2025 financial results, highlighting significant progress in its clinical programs. The company is preparing for a Biologics License Application (BLA) submission in the second quarter of 2026, seeking accelerated approval for nomlabofusp, a potential disease-modifying therapy for Friedreich’s ataxia. Larimar has strengthened its financial position with a recent public offering and is on track with its global Phase 3 study activities, aiming to initiate patient recruitment later in 2025. The FDA has recommended specific safety database requirements, and the company has published peer-reviewed articles supporting its regulatory strategy.

The most recent analyst rating on (LRMR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Larimar Therapeutics stock, see the LRMR Stock Forecast page.

Spark’s Take on LRMR Stock

According to Spark, TipRanks’ AI Analyst, LRMR is a Neutral.

Larimar Therapeutics’ stock score reflects its early-stage biotech status with high R&D costs, no consistent revenue, and reliance on equity financing. Despite positive short-term technical indicators suggesting upward momentum, the lack of profitability and a negative P/E ratio weigh heavily on the stock. Valuation concerns and the absence of earnings call insights further impact the score.

To see Spark’s full report on LRMR stock, click here.

More about Larimar Therapeutics

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company is advancing its nomlabofusp program, which targets Friedreich’s ataxia, a rare genetic disease.

Average Trading Volume: 1,323,181

Technical Sentiment Signal: Sell

Current Market Cap: $306.3M

Learn more about LRMR stock on TipRanks’ Stock Analysis page.